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Objective: Primary endometrioid adenocarcinoma of the cervix is a rare subtype of adenocarcinoma that has
often been misclassiﬁed in the literature due to the lack of clear-cut diagnostic criteria. A new classiﬁcation
system has recently been developed that aims to provide clarity and reproducibility when diagnosing subtypes of
endocervical adenocarcinoma. This case report demonstrates the diﬃculty in diagnosing primary endometroid
adenocarcinoma, application of the new diagnostic guidelines, and a review of the literature of this rare nonHPV subtype.
Case: A 76 year-old women presented with postmenopausal bleeding and was found to have an exophytic
cervical mass. Biopsies showed an adenocarcinoma of probable endometrial origin. She underwent a roboticassisted simple hysterectomy with bilateral pelvic lymph node sampling and omental biopsy. Final pathology
report demonstrated a primary endometrioid adenocarcinoma of the cervix, measuring 2.4 cm in size, diagnosed
using the recently developed International Endocervical Adenocarcinoma Criteria and Classiﬁcation (IECC)
system. Patient was then treated with external beam radiation therapy and concurrent chemotherapy, followed
by vaginal brachytherapy. She had no evidence of disease at her 15-month follow-up visit.
Conclusion: Primary endometrioid adenocarcinoma of the cervix is a rare and diagnostically challenging tumor
of the cervix. This case illustrates the challenges associated with diagnosis of this endocervical carcinoma
subtype and the need for a multi-disciplinary approach when determining treatment.

1. Introduction
The incidence of invasive endocervical adenocarcinoma (ECA) and
its variants has increased over the past few decades, accounting for
about 25% of cervical malignancies. This is in contrast to the more
prevalent invasive squamous cell carcinoma (SCC), whose incidence has
dramatically decreased in most developed countries due to the implementation of national screening and vaccination programs. SCC is
almost always human papillomavirus (HPV) related with the most
prevalent serotypes as HPV 18, 16, and 45. Although ECAs are commonly associated with HPV, 10–15% are non-HPV related (Stolnicu
et al., 2019).
ECA often presents with vaginal bleeding at a mean age of about
50 years of age (Kurman, 2014). On clinical exam, an exophytic mass or
ulcerated lesion maybe noted. Morphologically, ECAs are a heterogenous group with several distinct histological tumor types.

Traditionally, ECA have been classiﬁed according to the World Health
Organization (WHO) system (Kurman, 2014). This system has been
recently challenged by experts as it often diﬃcult to apply in daily
practice, lacks reproducibility, and lacks clinical signiﬁcance. The WHO
classiﬁcation also makes an assumption that all ECAs are HPV related.
To correct these failures, a panel of international experts developed the
International Endocervical Adenocarcinoma Criteria and Classiﬁcation
(IECC). The IECC classiﬁcation divides ECAs into two categories: HPVassociated (HPVA) and non-HPV-associated (NHPVA). NHPVA are then
subcategorized into ﬁve morphologically distinct groups: endometrioid,
gastric-type, serous, clear cell, mesonephric, and NOS (Stolnicu et al.,
2019; Stolnicu, 2018; Stolnicu, 2018) (Fig. 1).
Based upon the IECC classiﬁcation, endometrioid-type ECA is a rare
variant of ECA with an overall prevalence of 1.1% (Stolnicu, 2018).
This is in contrast to the WHO classiﬁcation system which reports the
prevalence of primary endometrioid adenocarcinoma between 7% and

⁎
Corresponding author at: Long Island Jewish Medical Center, Department of Obstetrics and Gynecology, 270-05 76th Avenue, 2nd Floor New Hyde Park, NY
11040, United States.
E-mail address: bbustamante@northwell.edu (B. Bustamante).

https://doi.org/10.1016/j.gore.2020.100579
Received 24 March 2020; Received in revised form 24 April 2020; Accepted 27 April 2020
Available online 01 May 2020
2352-5789/ © 2020 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).

Gynecologic Oncology Reports 32 (2020) 100579

K. Seay, et al.

Fig. 1. Endocervical adenocarcinoma classiﬁcation systems. (Kurman, 2014; Stolnicu, 2018).

50%. This discrepancy is based largely on the reclassiﬁcation of endometrioid-type ECA to usual-type ECA using the more stringent IECC
classiﬁcation (Stolnicu et al., 2019). We present a case herein of a rare
endometrioid-type ECA that was diagnosed using the criteria proposed
by IECC classiﬁcation.

2. Case
A 76 year old nulliparous female was referred to gynecology oncology for postmenopausal bleeding and an abnormal pap smear that
indicated HPV negative highly atypical epithelial cells, cannot determine glandular or squamous. Patient was noted on transvaginal ultrasound to have a uterus measuring 5 × 2.7 × 2.6 cm, with diﬀusely
heterogeneous endometrium raising possibility of a polyp despite the
normal thickness (3 mm.) History was signiﬁcant for an ovarian tumor
at age 20, status-post exploratory laparotomy and bilateral salpingooophorectomy. Patient was unable to provide information about histological type or stage but stated that she had not received adjuvant
treatment. Patient was diagnosed at age 73 with breast cancer, statuspost lumpectomy with no chemotherapy/radiation treatment indicated,
and was being treated with tamoxifen. Family history was signiﬁcant
for her mother and maternal aunt with breast cancer, and maternal aunt
with ovarian cancer. She had not undergone any genetic testing.
Patient was noted on physical exam to have an irregular polypoid
2–3 cm mass, inseparable from the cervix in the vaginal vault.
Parametria and rectovaginal septum were palpably smooth. Biopsy of
the mass revealed adenocarcinoma of probable endometrial origin, favoring high grade, as supported by ER positive, PR and p16 negative
immunohistochemical staining (IHC). Further characterization upon
deﬁnitive resection was needed.
CT chest, abdomen, and pelvis was obtained and showed no evidence of disease outside of the uterus. Patient underwent a roboticassisted simple hysterectomy with bilateral pelvic lymph node sampling
and omental biopsy. There was no gross evidence of extrauterine disease at time of surgery. Microscopically, the tumor showed an admixture of growth patterns, including glandular, papillary and micropapillary, with destructive stromal invasion (Fig. 2). Tumor cells
showed scant to moderate amount of eosinophilic to focally clear cytoplasm with intermediate nuclear grade and lack of mucin (Fig. 3). The
tumor did not extend to the lower uterine segment and endometrium
was unremarkable. IHC was signiﬁcant for a wild-type P53 pattern with

Fig. 2. Tumor inﬁltrating normal endocervical mucosa (4×, low power magniﬁcation, H&E).

Fig. 3. Tumor with glandular architecture and tumor cells exhibiting scant
eosinophilic cytoplasm and lack of mucin (20×, H&E).
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should be considered when radiotherapy is administered (Koh, 2019;
Baalbergen et al., 2013).
Prognosis of endometrioid-type ECA is unknown due to the rarity of
the disease. In general, the 5-year survival rate for women with invasive
cervical cancer is 92%. The major prognostic factors aﬀecting survival
include age, nodal status, tumor volume, and depth of invasion.
Although controversial, another prognostic factor is histologic type. A
study of 24,562 patients with cervical cancer demonstrated that among
women with early stage disease, patients with adenocarcinoma were
39% more likely to die compared to those with squamous cell carcinoma (Galic, 2012). An additional independent prognostic factor may
be HPV status of the tumor. Univariate analysis of the 187 cases published by Stolnicu et al. demonstrated signiﬁcant diﬀerence in the 5year survival between HPV-positive and HPV-negative adenocarcinomas that had received surgery and adjuvant treatment, with radiotherapy alone or in combination chemotherapy. The authors also found
that patients with HPV-positive adenocarcinoma with pelvic recurrence
had a better overall survival, disease free survival, and progression free
survival when compared to patients with NHPVA (Stolnicu, 2019).
However, further studies are needed to clarify the eﬀect of HPVstatus
on prognosis.
Post-treatment surveillance of patients with cervical cancers, including endometrioid-type ECA, consists of history and examination
every 3–6 months for 2 years, 6–12 months for 3–5 years, and then
annually based on patient’s risk of disease recurrence. Cervical/vaginal
cytology can be done annually. However, the likelihood of detecting an
asymptomatic recurrence by cytology alone is low. Experts recommend
that imaging and laboratory assessment should be reserved for those
individuals that present with symptoms or examination that is suspicious for disease recurrence (Koh, 2019).
In conclusion, we presented a rare case of endometrioid-type ECA
that was diagnosed using the IECC classiﬁcation system. This case
provides further supporting evidence of the strength of the IECC classiﬁcation system as it classiﬁes ECAs based upon HPV status. This case
also illustrates the challenges associated with diagnosis of this endocervical tumor subtype and the need for a multi-disciplinary approach when determining treatment.

positive staining for ER and CEA. Tumor cells were also focally positive
for P16 and TTF-1, negative for GATA3 and HR-HPV RNA. There was a
retained expression for PTEN, ARID1A, and DNA mismatch repair
proteins (MLH1, PMS2, MSH6, MSH2). Final pathology revealed a
2.4 cm tumor, invading at least 12 mm cervical stroma, focal tumor
present at cauterized circumferential margin, suspicious LVSI, negative
vaginal margin and lymph nodes. Based on these ﬁndings a ﬁnal diagnosis of stage IB1 non-HPV endometrioid-type ECA was rendered.
After discussion with a multi-disciplinary tumor board, the decision was
made for external beam radiation therapy and chemotherapy with
cisplatin 40 mg/m2 weekly for 6 weeks followed by vaginal brachytherapy for ﬁve treatments. The patient did well after surgery and
tolerated chemoradiation without incident. Follow-up exam and PET
CT with no evidence of disease at her 15 month post-surgery.
3. Discussion
Primary endometrioid adenocarcinoma is deﬁned by the WHO as an
ECA arising in the cervix that has endometrioid morphologic features,
such as tumor cells that are lacking mucin and have a scant, deeply
eosinophilic cytoplasm resembling endometrial-type epithelium.
Although widely used, many experts believe that this diagnostic criteria
is nonspeciﬁc and has led to discrepancies in reporting with incidence
of primary endometrioid adenocarcinoma ranging from 7% to more
than 50% (Stolnicu et al., 2019). In 2018, the IECC classiﬁcation was
published by Stolnicu et al. in order to provide clarity in diagnosing
ECA subtypes by linking morphological features to etiology (HPV
status) (Stolnicu, 2018). Using the IECC classiﬁcation, endometrioidtype ECA is deﬁned as endometrioid morphology with “conﬁrmatory
endometrioid features,” and lacking HPVA features, such as apical
mitoses and karyorrhexis. These “conﬁrmatory endometrioid features”
include at least focally identiﬁed low-grade endometrioid glands lined
by columnar cells, with pseudostratiﬁed nuclei demonstrating no more
than moderate atypia, with or without squamous diﬀerentiation, and/
or endometriosis present (Stolnicu, 2018; Lim, 2016). Using the WHO
classiﬁcation system, Stolnicu et al demonstrated that 41% of the 371
cases analyzed in their study would have been classiﬁed as endometrioid-type. However, using the IECC classiﬁcation, the majority
of those cases would be reclassiﬁed as usual-type ECAs, leaving only 3
cases of endometroid-type ECA (Stolnicu, 2018). The authors concluded
that this reclassiﬁcation is more in line with the etiology of endometroid-type ECAs as they are believed to arise from existing cervical
endometriosis (Stolnicu, 2018; Hirschowitz et al., 2007).
As a result of the lack of speciﬁc diagnostic criteria for endometrioid-type ECA, demographic and clinical parameters is diﬃcult
to determine. Recently, Stolnicu et al. published clinical outcomes for a
group of 187 cases diagnosed using the IECC classiﬁcation and had at
least a 5-year follow-up. The authors found that NHPVAs are generally
larger tumors, diagnosed at FIGO Stage II or more advanced in > 50%
of cases, and occur in older patients as compared to HPVA tumors.
NHPVAs were also more frequently associated with lymphvascular invasion, lymph node metastasis, and local and distant recurrence. Of
note, the predominant ECA in the NHPVAs cohort was gastric-type with
only two cases of endometrioid-like ECA used in the analysis (Stolnicu
et al., 2019; Stolnicu, 2019).
The National Comprehensive Cancer Network (NCCN) treatment
guidelines for cervical cancer does not diﬀerentiate treatment based
upon histological type. Treatment of early invasive adenocarcinoma
(IB1-IIA) typically consists of surgery (radical hysterectomy, bilateral
salpingo-oophorectomy, and pelvic lymph node dissection) or radiotherapy, which is usually administered with concurrent cisplatin-based
chemotherapy (Koh, 2019). Studies have shown an increased eﬀectiveness of surgery compared to radiotherapy (without chemotherapy)
in patients with adenocarcinoma. It has been postulated that this could
be the result of the increased eﬀectiveness of the surgery or a radioresistance of adenocarcinoma. Thus, experts agree that chemotherapy
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